NEW YORK and LONDON, March 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics , Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced it had
NEW YORK and LONDON , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics , Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that
• The new data show PAS-nomacopan (the long acting form of Akari’s lead drug, nomacopan) significantly reduced VEGF levels and retinal inflammation, both of which are associated with permanent damage in many back-of-the-eye diseases • PAS-nomacopan lowered intraocular levels of VEGF as
All patients treated with nomacopan have achieved the primary endpoint of transfusion independence Phase III interim data on the first eight PNH patients who were all transfusion dependent at entry to the CAPSTONE trial show that all four patients randomized to nomacopan were transfusion
NEW YORK and LONDON , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces that a U.S.
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based on guidance from End-of-Phase II meeting with U.S. Food and Drug Administration ( FDA ): Part A dose
- New data demonstrate dual role of C5 and LTB4 in both bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC). There are no U.S. Food and Drug Administration ( FDA )-approved treatments for either disease. - Clinical progress across our target conditions Phase II BP data demonstrated a
Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported finding These new findings suggest that inhibition of both LTB4 and C5 by nomacopan may provide therapeutic effect by reducing both
Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients – No reported drug-related serious adverse events – Achieved marked reduction in Bullous Pemphigoid Disease Area Index (BPDAI) activity score
NEW YORK and LONDON , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today